Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma

ConclusionsWhen combined with ipilimumab, epacadostat ≤50 mg BID demonstrated clinical and pharmacologic activity and was generally well tolerated in patients with advanced melanoma.Trial registrationClinicalTrials.gov identifier,NCT01604889. Registration date, May 9, 2012, retrospectively registered.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research